UK's NICE recommends use of Cimzia (certolizumab pegol) in active psoriatic arthritis- UCB
The National Institute for Health and Care Excellence is supporting use of Cimzia (certolizumab pegol), from UCB, alone, or in combination with methotrexate, for adults with active psoriatic arthritis if the person has had a TNF-alpha inhibitor but their disease has stopped responding after the first 12 weeks, and the drug is provided under the conditions of a patient access scheme.
Use should also follow existing NICE guidance psoriatic arthritis treatment with etanercept (Pfizer's Enbrel), infliximab (MSD's Remicade, Napp Pharmaceuticals' Remsima, and Hospira's Inflectra) and adalimumab (AbbVie's Humira), the Institute noted.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins